CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 228 enrolled
Drug / intervention
Methylphenidate transdermal system +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00889915
NCT00889915Phase 4Completed
CompareCT.gov

A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended Release (Adderall XR) in Children and Adolescents With ADHD

Duke University·interventional·Posted Apr 29, 2009·Updated Sep 30, 2013

In Brief

A Phase 4 clinical trial evaluating Methylphenidate transdermal system, Lisdexamfetamine dimesylate, and 2 other interventions for Attention Deficit Disorder With Hyperactivity. Completed, enrolled 228 participants across 1 site.

Detailed Summary

This study will determine whether two new psychostimulant medications are more effective, tolerable, and acceptable than two older medications for treating attention deficit hyperactivity disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Disorder With Hyperactivity
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 29, 2009
Enrollment StartApr 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.2 years ago

Interventions

Methylphenidate transdermal systemdrug

Not specified in protocol; determined by local standard of care.

Lisdexamfetamine dimesylatedrug

Not specified in protocol; determined by local standard of care.

Osmotic-release oral system methylphenidate (OROS MPH)drug

Not specified in protocol; determined by local standard of care.

Mixed amphetamine salts extended releasedrug

Not specified in protocol; determined by local standard of care.